Le Lézard
Classified in: Science and technology
Subject: TRADE SHOWS/SEMINARS/WEBINARS

Resonant to Present at 10th Annual LD Micro Main Event Investor Conference in Los Angeles on December 5th


GOLETA, CA--(Marketwired - November 21, 2017) - Resonant Inc. (NASDAQ: RESN), a designer of filters for radio frequency, or RF, front-ends that specializes in delivering designs for difficult bands and complex requirements, today announced that management is scheduled to present at the LD Micro Main Event Investor Conference in Bel Air, California. The conference is being held December 5-7, 2017 at the Luxe Sunset Boulevard Hotel in Bel Air, California.

Resonant management will host one-on-one meetings throughout the day on Tuesday, December 5, 2017, and is scheduled to present as follows:

LD Micro Main Event

Date: Tuesday, December 5, 2017

Presentation Time: 5:30 p.m. Pacific standard time

Location: Luxe Sunset Boulevard Hotel, Track 2 (11461 Sunset Blvd, Bel Air)

The presentation will be webcast and available following the live presentation. The webcast can be viewed at http://wsw.com/webcast/ldmicro13/resn/.

Conference participation is by invitation only and registration is mandatory. For more information or to schedule a one-on-one meeting, please contact an LD Micro representative.

About Resonant Inc.

Resonant is creating software tools and IP & licensable blocks that enable the development of innovative filter designs for the RF front-end, or RFFE, for the mobile device industry. The RFFE is the circuitry in a mobile device responsible for the radio frequency signal processing and is located between the device's antenna and its digital baseband. Filters are a critical component of the RFFE that selects the desired radio frequency signals and rejects unwanted signals and noise. For more information, please visit www.resonant.com.

About Resonant's ISN® Technology

Resonant can create designs for difficult bands and complex requirements that we believe have the potential to be manufactured for half the cost and developed in half the time of traditional approaches. The Company's large suite of proprietary mathematical methods, software design tools and network synthesis techniques enable it to explore a much bigger set of possible solutions and quickly derive the better ones. These improved filters still use existing manufacturing methods (i.e. SAW) and can perform as well as those using higher cost methods (i.e. BAW). While most of the industry designs surface acoustic wave filters using a coupling-of-modes model, Resonant uses circuit models and physical models. Circuit models are computationally much faster, and physical models are highly accurate models based entirely on fundamental material properties and dimensions. Resonant's method delivers excellent predictability, enabling achievement of the desired product performance in roughly half as many turns through the fab. In addition, because Resonant's models are fundamental, integration with its foundry and fab customers is eased because its models speak the "fab language" of basic material properties and dimensions.


These press releases may also interest you

at 06:18
Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment...

1 jun 2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data of its novel drug candidate...

1 jun 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

1 jun 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major...

1 jun 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

1 jun 2024
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the phase II trial data of KROCUS Study, fulzerasib (GFH925, KRAS G12C inhibitor) in combination with...



News published on and distributed by: